Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma
Sponsor study identifier
Secondary identifiers
interventional
4
1 country
1
Study Start
February 1989
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2007
Actual (reported)Study Completion
January 2008
Actual (reported)RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of methotrexate, mechlorethamine, vincristine, procarbazine, and prednisone in treating children with astrocytomas or primitive neuroectodermal tumors.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2008
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 1989
Date type not reportedThis date has not been verified as actual or estimated.
November 1, 1999
Actual (reported)April 22, 2004
Actual (reported)January 2007
Actual (reported)January 2008
Actual (reported)Number of Patient with Overall Response
Every 31 days
Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine
Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4009, United States
Ater J, Worth L, Bruner J, et al.: Young children treated with MOPP or methotrexate-MOP for medulloblastoma: identification of a subset of patients with good prognosis. [Abstract] Proceedings of the American Society of Clinical Oncology 14: A-1397, 1995.
Ater JL, van Eys J, Yung WK, et al.: Response to methotrexate, mechlorethamine, vincristine, procarbazine, and prednizone (MMOPP) for brain tumors. [Abstract] Proceedings of the American Society of Clinical Oncology 10: A-370, 125, 1991.
Joann Ater, MD
M.D. Anderson Cancer Center
4 participants (actual enrollment reported by the registry).
First Submitted
November 1, 1999
First Posted
April 22, 2004
Study Start
February 1989
Date type not reportedThis date has not been verified as actual or estimated.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Primary Completion
January 2007
Actual (reported)Study Completion
January 2008
Actual (reported)Last Updated
February 18, 2013
Record last verified: 2013-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: